05.19.25 -- Direct Access To Today's Leading CDMOs

In this presentation, we will highlight how our proven expertise and simplified execution with development, filling, and analytical under one roof ensure safe, efficacious products reach patients in need.

With expertise in process optimization, analytics, and regulatory strategy, we help partners de-risk development, accelerate time to market, and ensure manufacturability from the outset.

Backed by years of dedication to customer-focused solutions, we’re proud to introduce our specialists to the global biopharma community and share insights that drive innovation forward.

Evan Pasenello, Head of Commercial Services, gives viewers an update on how we can support manufacturing programs from clinical through commercial.

Executive Director of Technology and Business Development for Drug Product and Finished Goods, Henrik Herrmann, shares an update on the current and future state of FDB’s capabilities.

Uncover how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.

See first-hand how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.

Discover how NYBCe and CCS are transforming cell and gene therapy development with end-to-end CDMO solutions, advanced logistics, and a growing innovation hub in Louisville.

In this presentation, Shaan Gareeb highlights the capabilities of our Cell Therapy Center of Excellence in San Jose, California, one of five global Miltenyi Bioindustry sites.

Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.

Our integrated expertise — from plasmid science to viral vector and cell therapy manufacturing — can accelerate and de-risk the development of your advanced therapies.

Watch to see how we apply our expertise and know-how to efficiently advance your viral vector-based therapeutic through any phase, while enhancing quality and de-risking production.

Director of Commercial Development, Serat Ali, describes FDBs' Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.

Uncover how Integrated Unprocessed Bulk testing — including viral assays, NGS, and TEM — can safeguard product safety, minimize contamination risks, and streamline biologics development.

Caddy Hobbs, Ph.D., takes an in-depth look at our analytical services, which support the full drug development lifecycle — from early development through to commercial manufacturing.

Gain a strategic edge through customized solutions, reliable metrics, and a clear pathway to successful downstream testing, ensuring your therapeutics reach patients faster.

Accelerate your drug development and ensure regulatory compliance with our innovative analytical solutions and advanced nitrosamine testing strategies.

Get the quality, compliance, and accelerated development support you need for your small molecule and cell and gene therapy program with our advanced analytical testing services.